Master One Thing - Rapamycin Longevity Series cover image

Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

Master One Thing - Rapamycin Longevity Series

00:00

Projected Timelines to Approval

Joan estimates a possible approval for an aging indication around 2030 with expedited successful trials.

Play episode from 01:08:25
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app